Advertisement
UK markets open in 19 minutes
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,230.06
    +28.79 (+0.17%)
     
  • CRUDE OIL

    82.94
    +0.13 (+0.16%)
     
  • GOLD FUTURES

    2,330.80
    -7.60 (-0.33%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • Bitcoin GBP

    51,425.50
    -1,982.11 (-3.71%)
     
  • CMC Crypto 200

    1,390.87
    +8.30 (+0.60%)
     
  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

Amgen’s Xgeva Could Witness Revenue Growth in 2018

Amgen’s Xgeva Could Witness Revenue Growth in 2018

How Is Amgen Positioned for 2018? In January 2018, the FDA approved Amgen’s (AMGN) supplemental Biologics License Application (or sBLA) for Xgeva. Xgeva is used for the prevention of skeletal-related events in individuals with bone metastasis from solid tumors.